Market Intelligence, Clinical Progress, and High-Purity Reagents for Viral, Inflammatory, and Fibrotic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Cyclophilin A/PPIA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Cyclophilin A/PPIA Recombinant Protein (Wild-Type & Active-Site Mutants R55A, H126Q, etc.) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View Cyclophilin A/PPIA Products |
| Gene Delivery | Cyclophilin A/PPIA Promise-ORF / Lentivirus Full-length ORF for stable cell lines and intracellular target engagement assays. |
View Cyclophilin A/PPIA Products |
| Benchmark Ab | Anti-Cyclophilin A/PPIA (Reference Sequence) Recombinant positive control for extracellular interaction assays, Western blot, IP, and ELISA. |
View Cyclophilin A/PPIA Products |
| Validator | Cyclophilin A/PPIA siRNA Set For knockdown verification in functional cell assays and specificity controls. |
View Cyclophilin A/PPIA Products |
| Related Target A | CD147/BSG Primary extracellular receptor for secreted PPIA; crucial for chemotaxis and viral entry. |
View CD147/BSG Products |
| Related Target B | Calcineurin/PPP3CA Downstream effector complexed with PPIA-Cyclosporin; essential for immunosuppressive screening. |
View Calcineurin/PPP3CA Products |
| Related Target C | PPIB (Cyclophilin B) Paralog protein for counter-screening and selectivity assessment. |
View PPIB Products |
| Related Target D | PPID (Cyclophilin D) Mitochondrial isoform for counter-screening. |
View PPID Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Extracellular Functional False Positives | Strictly Endotoxin Controlled (<1EU/ug) to eliminate background inflammatory signaling in cellular assays. |
| Subfamily Cross-Reactivity (PPIA vs PPIB, PPIC, PPID, PPIG) | Homolog panel proteins (Sequence Verified, High Purity) available for precise selectivity profiling. |
| Lack of Reliable Controls | Recombinant Benchmark Antibodies included for SPR/ELISA standardization. |
| Intracellular Target Validation | Validated siRNA sets included for robust knockdown and specificity checks. |
| Enzymatic Activity Standardization | Sequence-verified wild-type PPIase domain with theoretical activity reference standards. |
Live Cyclophilin A/PPIA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Cyclophilin A/PPIA therapeutics is intensifying, with major players shifting focus from traditional broadly immunosuppressive agents (like Cyclosporin A) to highly selective Non-Immunosuppressive Cyclophilin Inhibitors (NICIs). As first-generation NICI therapies reach the clinic for liver fibrosis and viral infections, the next wave of R&D is heavily targeting the extracellular PPIA-CD147 signaling axis to treat acute systemic inflammation, neurodegeneration, and oncology. PPIA is experiencing renewed interest as a host-directed target across virology and immuno-oncology, with the pipeline shifting decisively toward non-immunosuppressive small molecules that retain high-affinity PPIA binding while structurally excluding calcineurin recruitment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / Peptidomimetic (Non-Immunosuppressive) | Hepion Pharmaceuticals, Debiopharm, Novartis, Takeda | NASH, Liver Fibrosis, HCV, SARS-CoV-2 | Selectivity Assay (Need High-Purity Homolog Panels PPIA vs PPIB/PPID/PPIG) |
| Monoclonal Antibodies | Emerging Biotechs | Acute Inflammation, Oncology, Rheumatoid Arthritis | PPIA-CD147 Blockade (Need Endotoxin-free ECD Proteins) |
| Targeted Degraders (PROTACs) | Academic/Early Pharma | Refractory Cancers | Ternary Complex Validation (Need Sequence-Verified Antigens) |
| Host-directed Antiviral / Macrocycle | Emerging Biotech | Respiratory Viral Disease, Persistent Viral Reservoirs | Cell-based infection assay with stable PPIA KD/OE cell lines |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Subfamily Selectivity: Human cyclophilin family includes at least 16 members (PPIA, PPIB, PPIC, PPID, PPIG, etc.). Broad inhibition can cause systemic toxicity; selective PPIA inhibition is critical.
- Mechanism (Immunosuppressive Liability): NICIs must prove they do not form the drug-PPIA-calcineurin ternary complex, requiring precise in vitro binding validation.
- Intracellular vs Extracellular Targeting: Small molecules need cell permeability and intracellular target engagement; biologics must block extracellular PPIA-CD147 interaction without inducing receptor internalization.
- Resistance Mutations: Active-site mutations (R55A, H126Q, F60A) can lead to acquired resistance; mutant panels are essential for profiling.
Core Screening Assay Recommendations
- High-Throughput Selectivity Panel: Use recombinant PPIA, PPIB, PPIC, PPID proteins in PPIase enzymatic inhibition assays.
- Ternary Complex Exclusion Assay (SPR/TR-FRET): Immobilize Calcineurin A/B; flow drug-PPIA complex. Good NICIs should show no binding signal.
- Extracellular Blockade ELISA / Chemotaxis Assay: Use high-purity recombinant PPIA to test antibody blockade of CD147 binding or macrophage chemotaxis.
- Cellular Thermal Shift Assay (CETSA): Validate intracellular target engagement using PPIA lentivirus stable cell lines.
The TarMart Advantage
- Ultra-Low Endotoxin (<1 EU/ug): Ensures chemotaxis signals are driven solely by PPIA-CD147 axis, avoiding false positives.
- High Purity (>95%) & Sequence Verified: Guarantees accurate SPR/Biacore kinetics and reliable ternary complex validation.
- Mutant Panel Availability: Supports resistance mechanism studies and allosteric site validation.
Related Targets for Cross-Selling
- CD147/BSG: Core receptor for extracellular PPIA; essential for PPI blockade experiments.
- Calcineurin (PPP3CA/PPP3R1): Required for screening out immunosuppressive activity (NICI validation).
- PPIB (Cyclophilin B): ER-resident paralog for counter-screening and selectivity assessment.
- PPID (Cyclophilin D): Mitochondrial isoform for counter-screening to avoid apoptosis liability.